Peptide Based Antibacterial Coating

肽基抗菌涂层

基本信息

批准号：
7497561
负责人：
Jennifer Ann Neff
金额：
$ 42.32万
依托单位：
ALLVIVO VASCULAR, INC.
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-20 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7497561
关键词：
Adsorption Anti-Bacterial Agents Antibiotic Resistance Antibiotics Bacteria Binding Blood Proteins Blood Vessels Catheters Charge Clinical Clinical Trials Condition Coupled Crosslinker Dental Devices Effectiveness Electrostatics Ensure Evaluation Goals Government Gram-Negative Bacteria Gram-Positive Bacteria Heating Hemolysis Human In Vitro Industrial Product Infection Infection prevention Lead Licensing Marketing Measures Medical Medical Device Methicillin Resistance Methods Microbial Biofilms Modeling Nisin Nitrilotriacetic Acid Object Attachment Optics Oxides PEO-PPO-PEO Pediococcus Peptides Performance Persons Phase Physiological Polyethylene Glycols Polymers Polypropylenes Polyurethanes Preclinical Testing Process Production Property Proteins Purpose Rattus Relative (related person)Resistance Risk Sales Serum Services Small Business Funding Mechanisms Small Business Innovation Research Grant Staging Staphylococcus aureus Staphylococcus epidermidis Surface Technology Testing Thrombus Time Venous Work antimicrobial base clinically relevant clinically significant commercial application commercialization copolymer cost effective day implantation in vivo irradiation killings novel prevent programs prototype research and development sound surfactant

项目摘要

DESCRIPTION (provided by applicant): The objective of this work is to develop dual function antibacterial coatings that prevent biofilm formation and thrombus. A key feature of this technology is that it will prevent biofilm formation without an associated risk of creating antibiotic resistant bacteria. The coating combines a novel protein resistant polymer with an antibacterial peptide. The peptide kills bacteria through a multi- tiered mechanism that is fundamentally different from that of clinical antibiotics and is therefore unlikely to promote resistance. Coatings will be produced by binding the peptide to surfaces in two modes: via a flexible tether and entrapment. A layer of the antibacterial peptide prepared in this way should be safe, functional, and long-lasting. This Phase II SBIR plan focuses on meeting requirements for short term central venous catheters. First, coating constituents will be selected to maximize activity. Activity and mode of action will be characterized with a close look at covalently tethered versus physically bound peptides. As a part of this process, structural and functional relationships of surface bound antimicrobials will be examined. Second, methods will be developed to ensure robust performance of coatings under physiological conditions. Efficacy over time under these conditions will be measured, where efficacy criteria include biofilm inhibition as well as nonthrombogenicity. Prototype catheters coated with this technology will then be produced and tested against clinically relevant bacteria including methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis. The plan will be completed with an in vivo evaluation of prototypes using a model of central venous catheter infection in rats. Commercial applications include catheters, medical, optical and dental devices.

描述（由申请人提供）：这项工作的目的是开发防止生物膜形成和血栓的双功能抗菌涂层。该技术的一个关键特征是，它将防止生物膜形成，而不会产生产生抗生素抗性细菌的相关风险。该涂层结合了新型抗蛋白聚合物和抗菌肽。该肽通过多层机制杀死细菌，该机制与临床抗生素的机制根本不同，因此不太可能促进耐药性。涂层将通过将肽以两种模式结合到表面来产生：通过柔性系链和包埋。以这种方式制备的一层抗菌肽应该是安全的、功能性的和持久的。该第二期 SBIR 计划的重点是满足短期中心静脉导管的要求。首先，选择涂层成分以最大限度地提高活性。将通过仔细研究共价连接肽与物理结合肽来表征活性和作用模式。作为该过程的一部分，将检查表面结合抗菌剂的结构和功能关系。其次，将开发方法以确保涂层在生理条件下的稳健性能。将测量在这些条件下随时间推移的功效，其中功效标准包括生物膜抑制以及非血栓形成性。然后将生产涂有该技术的原型导管，并针对临床相关细菌进行测试，包括耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌菌株。该计划将通过使用大鼠中心静脉导管感染模型对原型进行体内评估来完成。商业应用包括导管、医疗、光学和牙科设备。